The present invention provides a method for preventing, postponing or treating ocular diseases, including changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment. The method comprises administering to a subject an effective amount of Cordyceps cicadae mycelium active substances. A method for preparing Cordyceps cicadae mycelium active substances comprises following steps: (a) culturing a Cordyceps cicadae mycelium on a plate medium between 15-35 C. for 5-14 days; (b) inoculating the Cordyceps cicadae mycelium of step (a) into a flask and culturing the mycelium between 15-35 C. and pH 2-8 for 3-7 days; and (c) inoculating the Cordyceps cicadae mycelium of step (b) into a fermenter tank and culturing the mycelium by stirring between 15-35 C. and pH 2-8 for 3-5 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing the Cordyceps cicadae mycelium active substances.

The present invention provides a method for preventing, postponing or treating ocular diseases, including changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment. The method comprises administering to a subject an effective amount of Cordyceps cicadae mycelium active substances. A method for preparing Cordyceps cicadae mycelium active substances comprises following steps: (a) culturing a Cordyceps cicadae mycelium on a plate medium between 15-35 C. for 5-14 days; (b) inoculating the Cordyceps cicadae mycelium of step (a) into a flask and culturing the mycelium between 15-35 C. and pH 2-8 for 3-7 days; and (c) inoculating the Cordyceps cicadae mycelium of step (b) into a fermenter tank and culturing the mycelium by stirring between 15-35 C. and pH 2-8 for 3-5 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing the Cordyceps cicadae mycelium active substances.

The present invention provides compositions formulated for topical administration to a penis of a person to enhance sexual responsiveness in the person, to enhance sexual performance, erection and stamina, and to increase the physical size of the penis, where the compositions comprise active components from herbal or plant origin including maca, tongkat ali, cordyceps, ginseng, fructus schisandrae. morinda root, rhodiola, rosea cordyceps sinensis, ginger, jasmine, sandalwood, leeks, camellia seed, jojoba oil and cannabidiol. The preferred composition is in the form of a massage oil, to be applied topically to the skin of the penis.

The present invention provides compositions formulated for topical administration to a penis of a person to enhance sexual responsiveness in the person, to enhance sexual performance, erection and stamina, and to increase the physical size of the penis, where the compositions comprise active components from herbal or plant origin including maca, tongkat ali, cordyceps, ginseng, fructus schisandrae. morinda root, rhodiola, rosea cordyceps sinensis, ginger, jasmine, sandalwood, leeks, camellia seed, jojoba oil and cannabidiol. The preferred composition is in the form of a massage oil, to be applied topically to the skin of the penis.

A pharmaceutically acceptable formulation comprising a cannabinoid, e.g., CBG, CBGA, CBGV, and CBGVA, or a pharmaceutically acceptable salt or ester thereof, substantially without CBDA synthase products and TCHA synthase products; and at least one additional active composition, e.g., an endocannabinoid, dextromethorphan, melatonin, 5-hydroxy tryptophan, or serotonin. The cannabinoid may be a full spectrum or broad spectrum extract of a plant of genus Cannabis, containing cannabinoids, terpenes, and flavonoids, and substantially without cannabidiol and tetrahydrocannabinol. The composition may be a pharmaceutically acceptable formulation for oral, mucosal (including sublingual), topical, inhaled, vaporized or spray, or smoked administration. The formulation may include absorption or pharmacological (synergistic) exogenous enhancers, e.g., curcumin, resveratrol, quercetin, piperine, butyrate (or its natural derivatives) and other (endo)cannabinoids. The composition may have anti-inflammatory properties beneficial as a prophylaxis or therapy of symptoms due to SARS-Cov2 infection.

As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features methods for treating neurological conditions (e.g., traumatic brain injury or TBI), or symptoms thereof (e.g., anxiety or depression), with a cannabidiol and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment of neurological conditions (e.g., TBI), or symptoms thereof (e.g., anxiety or depression).

As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features methods for treating neurological conditions (e.g., traumatic brain injury or TBI), or symptoms thereof (e.g., anxiety or depression), with a cannabidiol and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment of neurological conditions (e.g., TBI), or symptoms thereof (e.g., anxiety or depression).

A cannabinoid composition, comprising a full spectrum extract of a plant of genus cannabis comprising at least 5% by weight cannabigerol, comprising cannabis terpenes and cannabis flavonoids, and substantially without cannabidiol and tetrahydrocannabinol. The composition may be a pharmaceutically acceptable formulation for oral, sublingual, inhaled, vaporized, or smoked administration. The formulation may include absorption or pharmacological enhancers e.g., curcumin, resveratrol, quercitin, piperine and/or N-alkylamides. The composition has anti-inflammatory properties beneficial as a prophylaxis or therapy of symptoms due to SARS-Cov2 infection.

A cannabinoid composition, comprising a full spectrum extract of a plant of genus cannabis comprising at least 5% by weight cannabigerol, comprising cannabis terpenes and cannabis flavonoids, and substantially without cannabidiol and tetrahydrocannabinol. The composition may be a pharmaceutically acceptable formulation for oral, sublingual, inhaled, vaporized, or smoked administration. The formulation may include absorption or pharmacological enhancers e.g., curcumin, resveratrol, quercitin, piperine and/or N-alkylamides. The composition has anti-inflammatory properties beneficial as a prophylaxis or therapy of symptoms due to SARS-Cov2 infection.

A method for treating renal disease is provided in the present invention, and the method includes the step(s) of: administering a Cordyceps militaris extract to a subject in need thereof. Preferably, the Cordyceps militaris extract is manufactured by a method including the step(s) of: grinding a fruiting body of Cordyceps militaris into powders; mixing the Cordyceps militaris powders with ethanol to obtain a mixture; filtering the mixture to obtain a filtrate; and drying the filtrate to obtain the Cordyceps militaris extract.